3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
140
Leukemia
132
Lymphoma
90
Leukemia, Myeloid, Acute
62
Myelodysplastic Syndromes
47
Burkitt Lymphoma
46
Lymphoma, Non-Hodgkin
44
Lymphoma, Large B-Cell, Diffuse
37
Breast Neoplasms
37
Lymphoma, Mantle-Cell
33
Leukemia, Lymphocytic, Chronic, B-Cell
33
Hodgkin Disease
32
Multiple Myeloma
29
Congenital Abnormalities
29
Myeloproliferative Disorders
27
Lymphoma, Follicular
27
Leukemia, Myeloid, Accelerated Phase
27
Graft vs Host Disease
27
Leukemia, Myelomonocytic, Chronic
25
Lymphoma, Large-Cell, Immunoblastic
24
Leukemia, Myeloid, Chronic-Phase
24
Blast Crisis
24
Lymphoma, B-Cell, Marginal Zone
22
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
20
Anemia, Refractory, with Excess of Blasts
20
Recurrence
18
Primary Myelofibrosis
17
Neoplasms, Plasma Cell
17
Dendritic Cell Sarcoma, Interdigitating
17
Osteosarcoma
16
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
Methotrexate
×
Clear all
NCT00022516
2016-09-16
22-00
ETOP IBCSG Partners Foundation
Phase 3
Completed
1,086 enrolled
10 charts